POS-662 5-YEAR SURVIVAL RATE OF CONTINUOUS AMBULATORY PERITONEAL DIALYSIS IN END-STAGE RENAL DISEASE IN INDONESIA: CAN CAPD BE SOLUTION FOR ESRD IN LOW INCOME DEVELOPING COUNTRY?

Abstract

There are an increase in End-Stage Renal Disease (ESRD) patients in developing countries every year, including Indonesia. Based on the 2018 Indonesian Basic Health Research, 3.8 ‰ of the Indonesian population is ESRD patient. The number of available hemodialysis machines and hemodialysis nurses in Indonesia is far from optimal, and the number of procedures and success rate of kidney transplants is still very low. Considering those limitations, Continuous Ambulatory Peritoneal Dialysis (CAPD) therapy is chosen as an option for renal replacement therapy in Indonesia. This study is aimed to report the 5-year survival of ESRD patients undergoing CAPD therapy in low income developing countries such as Indonesia. A retrospective cohort study was conducted involving 674 ESRD patients undergoing CAPD therapy. Data was taken from medical records from Malang CAPD Center of Saiful Anwar Hospital from August 2014 to July 2020. The 5-year survival rate and hazard ratio were analyzed using Kaplan-Meier and cox-regression analysis, respectively. 674 ESRD patients undergoing CAPD, 63.2% of patients survived up to 5 years with a general survival rate at 1, 3, and 5 years of 80%, 60%, and 52%, respectively. The 3-year survival rate of CAPD therapy in ESRD patients with comorbid hypertension and type II diabetes mellitus was 80% and 10%, respectively. The hazard ratio of ESRD patients on CAPD therapy with comorbid type II diabetes mellitus was 8.4 times (95% CI = 6.36-11.21). The 5-year survival rate of ESRD patients with CAPD therapy in Indonesia was good. Patients with comorbid type II diabetes mellitus had a worse survival rate. With all the problems of hemodialysis and kidney transplantation that exist in low income developing countries, CAPD can be a solution for renal replacement therapy.